DOR BioPharma to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference
November 07 2005 - 7:00AM
Business Wire
DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the "Company"), announced
today that Evan Myrianthopoulos, Chief Financial Officer of DOR,
will be presenting at the Rodman & Renshaw Techvest 7th Annual
Healthcare Conference on Wednesday, November 9, 2005 at 8:40 AM EDT
at the New York Palace Hotel in New York. Mr. Myrianthopoulos will
provide a review of DOR's planned acquisition of Gastrotech Pharma
and other anticipated events relating to the Company's
biotherapeutic and biodefense programs. The presentation will be
webcast live and may be accessed by visiting DOR's website at
www.dorbiopharma.com. A replay of the webcast will be available on
DOR's website for approximately 30 days following the presentation.
About DOR BioPharma, Inc. DOR BioPharma, Inc. is a
biopharmaceutical company focused on the development of therapeutic
products and biomedical countermeasures for areas of unmet medical
need. Our lead product, orBec(R) (oral beclomethasone
dipropionate), is a potent, locally-acting corticosteroid being
developed for the treatment of intestinal Graft-versus-Host disease
(iGVHD), a common serious complication of bone marrow
transplantation for cancer, as well as other GI disorders
characterized by severe inflammation. We plan to file a new drug
application (NDA) with the FDA for orBec(R) for the treatment of
iGVHD in early 2006. Through our BioDefense Division, we are
developing biomedical countermeasures pursuant to the paradigm
established by the recently enacted Project BioShield Act of 2004.
Our biodefense products in development are bioengineered vaccines
designed to protect against the deadly effects of ricin toxin and
botulinum toxin, both of which are considered serious bioterrorism
threats. Our ricin toxin vaccine, RiVax(TM), has completed the
clinical portion of its Phase I clinical trial in normal
volunteers. We have also announced the initiation of a new
botulinum toxin therapeutic development program based on rational
drug design. For further information regarding DOR BioPharma,
please visit the Company's website located at
http://www.dorbiopharma.com. This press release contains
forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, that reflect DOR BioPharma's
current expectations about its future results, performance,
prospects and opportunities, including statements regarding the
potential use of orBec(R) for the treatment of iGVHD and the
prospects for regulatory filings for orBec(R). Where possible, DOR
BioPharma has tried to identify these forward-looking statements by
using words such as "anticipates", "believes", "intends", or
similar expressions. These statements are subject to a number of
risks, uncertainties and other factors that could cause actual
events or results in future periods to differ materially from what
is expressed in, or implied by, these statements. DOR BioPharma
cannot assure you that it will be able to successfully develop or
commercialize products based on its technology, including orBec(R),
particularly in light of the significant uncertainty inherent in
developing vaccines against bioterror threats, manufacturing and
conducting preclinical and clinical trials of vaccines, and
obtaining regulatory approvals, that its technologies will prove to
be safe and effective, that its cash expenditures will not exceed
projected levels, that it will be able to obtain future financing
or funds when needed, that product development and
commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further grants and
awards, maintain its existing grants which are subject to
performance, enter into any biodefense procurement contracts with
the U.S. Government or other countries, that it will be able to
patent, register or protect its technology from challenge and
products from competition or maintain or expand its license
agreements with its current licensors, that it will be able to
maintain its listing on the American Stock Exchange ("AMEX") by
completing a transaction which will provide it with shareholders'
equity of at least $6 million prior to a date set by AMEX for a
hearing regarding the continued listing on AMEX of Dor BioPharma's
common stock, or that its business strategy will be successful.
Important factors which may affect the future use of orBec(R) for
iGVHD include the risks that: because orBec(R) did not achieve
statistical significance in its primary endpoint in the pivotal
Phase III clinical study (i.e. a p-value of less than or equal to
0.05), the FDA may not consider orBec(R) approvable based upon
existing studies, orBec(R) may not show therapeutic effect or an
acceptable safety profile in future clinical trials, if required,
or could take a significantly longer time to gain regulatory
approval than DOR BioPharma expects or may never gain approval; Dor
BioPharma is dependent on the expertise, effort, priorities and
contractual obligations of third parties in the clinical trials,
manufacturing, marketing, sales and distribution of its products;
or orBec(R) may not gain market acceptance; and others may develop
technologies or products superior to orBec(R). Dor BioPharma's
business strategy has been revised to include the issuance of its
securities to acquire companies or assets. Dor BioPharma presently
is involved in negotiations which could result in the issuance of a
significant number of shares of its equity securities, thereby
diluting the equity interests of present stockholders. These and
other factors are described from time to time in filings with the
Securities and Exchange Commission, including, but not limited to,
DOR BioPharma's most recent reports on Form 10-QSB and Form 10-KSB.
DOR BioPharma assumes no obligation to update or revise any
forward-looking statements as a result of new information, future
events, and changes in circumstances or for any other reason.
Dor (AMEX:DOR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dor (AMEX:DOR)
Historical Stock Chart
From Aug 2023 to Aug 2024